Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Marco Capozzoli"'
Autor:
Giacomo Emmi, Bruno Frediani, Mauro Galeazzi, Fiorella Fusco, Claudia Fabiani, Giuseppe Lopalco, Alice Bitossi, Gian Marco Tosi, Ida Orlando, Luca Cantarini, Antonio Vitale, Lorenzo Vannozzi, Francesco Rana, Jurgen Sota, Silvana Guerriero, Florenzo Iannone, Marco Capozzoli
Publikováno v:
Clinical Rheumatology. 38:63-70
The aim of the present study was to compare long-term adalimumab (ADA) and infliximab (IFX) retention rates in patients with intermediate, posterior, or panuveitis. Additional aims are as follows: (i) to identify any difference in the causes of treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b9e7412f7dfb75a77759e87d97e56a1
https://doi.org/10.1007/s10067-018-4069-3
https://doi.org/10.1007/s10067-018-4069-3
Autor:
Marco Capozzoli, Jurgen Sota, Mauro Galeazzi, Antonio Vitale, Luca Cantarini, Claudia Fabiani, Gian Marco Tosi, Rossella Franceschini, Ida Orlando, Bruno Frediani
Publikováno v:
Internal and Emergency Medicine. 12:947-955
Our aim was to prospectively investigate the impact of Behcet's disease (BD), disease activity, and clinical and demographic characteristics on different aspects of quality of life (QoL) measured by the short-form (SF)-36 QoL scale. We administered t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1134d21e045d8df5aa29a3822942ec1
https://doi.org/10.1007/s11739-017-1691-z
https://doi.org/10.1007/s11739-017-1691-z
Autor:
Bruno Frediani, Florenzo Iannone, Gian Marco Tosi, Ida Orlando, Claudia Fabiani, Mauro Galeazzi, Gerardo Di Scala, Marco Capozzoli, Jurgen Sota, Antonio Vitale, Silvana Guerriero, Donato Rigante, Rossella Franceschini, Giacomo Emmi, Luca Cantarini, Lorenzo Vannozzi, Giuseppe Lopalco
Publikováno v:
Clinical rheumatology. 37(6)
To identify clinical variables capable of predicting long-term treatment duration of TNF-α inhibition in patients with Behcet's disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532919f1a4434a539da207aa14dcf6db
https://pubmed.ncbi.nlm.nih.gov/29671190
https://pubmed.ncbi.nlm.nih.gov/29671190
Autor:
Mauro Galeazzi, Giacomo Emmi, Bruno Frediani, Giuseppe Lopalco, Claudia Fabiani, Silvana Guerriero, Marco Capozzoli, Daniela Bacherini, Rossella Franceschini, Jurgen Sota, Florenzo Iannone, Luca Cantarini, Gian Marco Tosi, Stefano Gentileschi, Antonio Vitale, Lorenzo Vannozzi, Donato Rigante
Background/aimsAdalimumab (ADA) has been shown to be an effective treatment for Behçet’s disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period in patients with BD-related uveit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0b7d4e4a6ba5c66e8a70ff65f232348
http://hdl.handle.net/11365/1050876
http://hdl.handle.net/11365/1050876
Publikováno v:
International ophthalmology. 39(4)
Fingolimod is the first oral drug approved for treatment of relapsing–remitting multiple sclerosis (RR-MS), and it has potential macular side effects. Despite the qualitative evidence of macular oedema under treatment, longitudinal quantitative ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7a0233aa67f8bcf0fa82a356d05d7ee
https://pubmed.ncbi.nlm.nih.gov/29500696
https://pubmed.ncbi.nlm.nih.gov/29500696
Autor:
Mario Fruschelli, Lara Aprile, Stefano Fazio, Theodora Hadjistilianou, Marco Capozzoli, Anna Sicuranza, Luca Puccetti, G. Chimenti
Publikováno v:
Acta Ophthalmologica. 94
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4bce5305d9f2ccc46119654f11dd07b
https://doi.org/10.1111/j.1755-3768.2016.0542
https://doi.org/10.1111/j.1755-3768.2016.0542
Publikováno v:
Acta Ophthalmologica. 93
Purpose To investigate potential mechanisms involved in retinal vein occlusion (RVO) we evaluated thrombin generation and soluble CD40 ligand (sCD40L) with respect to other known thrombophilic factors. Methods 68 patients affected by RVO (28 central,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91c9324925c42828cfcadf219e58a8b9
https://doi.org/10.1111/j.1755-3768.2015.0496
https://doi.org/10.1111/j.1755-3768.2015.0496